Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) regularly issues news and press releases that are of interest to investors, analysts and others following the health care services and durable medical equipment space. The company describes itself as a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, with operations organized into Patient Services and Device Solutions platforms.
News items about InfuSystem often include quarterly and annual financial results, where the company discusses net revenues, segment performance for Patient Services and Device Solutions, gross margin trends, cash flow, and Adjusted EBITDA. These releases typically highlight how oncology, pain management and wound therapy within Patient Services, as well as rentals, pump and consumable sales, and biomedical services within Device Solutions, have contributed to overall results.
Another common category of news involves guidance and outlook. InfuSystem has used press releases to provide or reaffirm guidance ranges for net revenue growth and Adjusted EBITDA margin for upcoming fiscal years, and to explain how factors such as revenue mix, information technology projects, and capital expenditures may affect margins and cash flow.
The company also issues announcements about leadership changes and corporate governance, such as the CEO transition disclosed in April 2025, and about participation in investor conferences hosted by firms like ROTH and Craig-Hallum. These items often note that management will host one-on-one or small group meetings with investors.
In addition, InfuSystem uses news releases to communicate regulatory and policy developments that affect its business. For example, an 8-K dated December 10, 2025 references a press release announcing that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
Visitors to the INFU news page can review this stream of financial updates, guidance, leadership announcements, conference participation notices and regulatory disclosures to understand how the company describes its performance and strategic priorities over time.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced its third quarter 2022 financial results will be issued on November 8, 2022, before the market opens. A conference call will follow at 9:00 a.m. Eastern Time to discuss the financial outcomes. Interested parties can join by dialing (833) 366-1127 or via a live webcast on the company’s website. InfuSystem provides healthcare services focusing on outpatient care for durable medical equipment manufacturers, with operations across several U.S. states and Canada.
InfuSystem Holdings, Inc. (NYSE American: INFU) appointed R. Rimmy Malhotra as an independent director, effective September 20, 2022. Malhotra, who invested in the company in 2012, brings valuable insights on investments and capital allocation. His appointment is expected to enhance the company’s governance and strategic direction as it aims for long-term growth. Malhotra has extensive experience in investment and management, serving as Vice Chairman of HireQuest Inc. and on various other boards, complementing InfuSystem's focus on outpatient care for durable medical equipment.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced participation in Lake Street Capital Markets' 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022, in New York City. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors. The BIG6 Conference is an exclusive event that connects top public companies with institutional investors. InfuSystem specializes in outpatient care and durable medical equipment services, focusing on Integrated Therapy Services and Durable Medical Equipment Services.
InfuSystem Holdings reported Q2 2022 net revenues of $27 million, marking a 9% increase year-over-year. Integrated Therapy Services (ITS) revenues grew 6% to $17.2 million, while Durable Medical Equipment (DME) revenues surged 15% to $9.8 million. Despite revenue growth, gross profit fell 1% to $14.9 million with a gross margin decline to 55.1%. The company posted a net loss of $0.2 million or $(0.01) per diluted share. Adjusted EBITDA was $5.5 million, a 6% decrease. Full-year revenue guidance was revised to 10%-13% growth.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the release of its second quarter 2022 financial results on August 4, 2022, before market opening. A subsequent conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss these results. InfuSystem specializes in outpatient care services for durable medical equipment, operating two main platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Services include oncology, pain management, and more.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national sales and marketing agreement with Ventis Pharma for its Endura-Kit™, a patented local anesthetic compound. This collaboration aims to enhance pain management solutions, focusing on opioid alternatives through multi-modal approaches. The Endura-Kit™ combines three non-opioid drugs, designed to improve post-operative and chronic pain management effectively. This partnership is expected to expand InfuSystem's revenue streams and enhance their service offerings.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced that its CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will participate in the Craig-Hallum's 19th Annual Institutional Investor Conference on June 1, 2022. This event will be held virtually, and management will conduct one-on-one meetings throughout the day. Interested investors can reach out to Craig-Hallum or contact Lytham Partners at 602-889-9700 or via email at infu@lythampartners.com. InfuSystem is a national healthcare service provider, specializing in outpatient care for durable medical equipment.
InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.
InfuSystem Holdings, Inc. (NYSE American: INFU) has secured a three-year master service agreement with a leading global healthcare technology company, effective April 25, 2022. This agreement involves providing maintenance and repair services for over 300,000 infusion pumps across more than 1,200 medical facilities in North America. The estimated annual revenue from this contract is between $10 million and $12 million. The CEO emphasizes this partnership as a foundation for growth in their Durable Medical Equipment (DME) services segment.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2022 financial results on May 5, 2022, before market opening. A conference call will follow at 9:00 a.m. Eastern Time for discussion of the results. Interested parties can participate by calling (888) 567-1603 or via live webcast at the company's website. InfuSystem specializes in outpatient care for durable medical equipment, operating through its Integrated Therapy Services and Durable Medical Equipment Services platforms.